Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 15/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29136864 | 1.00 | KLKB1 (0.41) | KLKB1METTL3TYK2DGAT1ACVRL1 | |
| SCHEMBL24737729 | 1.00 | KLKB1 (0.41) | KLKB1METTL3TYK2DGAT1ACVRL1 | |
| SCHEMBL29136863 | 1.00 | KLKB1 (0.41) | KLKB1METTL3TYK2DGAT1ACVRL1 | |
| SCHEMBL29879527 | 1.00 | KLKB1 (0.41) | KLKB1METTL3TYK2DGAT1ACVRL1 | |
| SCHEMBL29137049 | 1.00 | KLKB1 (0.41) | KLKB1METTL3TYK2DGAT1ACVRL1 | |
| SCHEMBL24737654 | 0.91 | KLKB1 (0.39) | KLKB1METTL3TYK2 | |
| SCHEMBL29302923 | 0.91 | KLKB1 (0.38) | KLKB1METTL3TYK2ACVRL1 | |
| SCHEMBL29136908 | 0.91 | KLKB1 (0.41) | KLKB1METTL3 | |
| SCHEMBL29879291 | 0.91 | KLKB1 (0.41) | KLKB1METTL3 | |
| SCHEMBL29136802 | 0.91 | KLKB1 (0.41) | KLKB1METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |